Oncology

  • FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL

    on June 22nd, 2017
    The Food and Drug Administration has approved rituximab plus hyaluronidase human for adult patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). The combination product, to be marketed as Rituxan Hycela, is administered subcutaneously,[...]
  • Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL

    on June 22nd, 2017
    AT ASCO 2017 CHICAGO (FRONTLINE MEDICAL NEWS) – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic leukemia (CLL), based on results from the phase 2 CALGB 10404 trial. This unique survival plateau indicates future [...]
  • For opioid-related hospitalizations, men and women are equal

    on June 22nd, 2017
    Equality is not always a good thing, particularly with opioids. In 2005, the rate of opioid-related inpatient hospital stays was 145.6 per 100,000 population for males of all ages and 127.8 for females of all ages. By 2014, however, equality had arrived: Females had a rate of 224.1 per 100,000, comp[...]
  • ACOG recommends women start mammography between ages 40 and 50 years

    on June 22nd, 2017
    Woman at average risk for breast cancer should be offered their first screening mammogram at age 40, with initiation of screening beginning no later than age 50, according to new recommendations from the American College of Obstetricians and Gynecologists. ACOG suggested a screening interval of 1-2 [...]
  • Bendamustine plus rituximab may have edge for treating indolent NHL, MCL

    on June 22nd, 2017
    AT ASCO 2017 CHICAGO (FRONTLINE MEDICAL NEWS) – Overall survival was comparable at 5 years of follow up for three regimens in treatment-naive patients with indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL), based on long-term results from the BRIGHT study. While progression-free su[...]
  • Lenalidomide-rituximab induces high CR rate in untreated follicular lymphoma

    on June 22nd, 2017
    AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – The chemotherapy-free combination of lenalidomide (Revlimid) and rituximab was highly active as frontline therapy for patients with low- and intermediate-risk follicular lymphoma in a multicenter phase II trial. Among 66 patients with previ[...]
  • Liver disease doubles risk of colorectal cancer

    on June 21st, 2017
    FROM GASTROINTESTINAL ENDOSCOPY Chronic liver disease appears to double the risk of colorectal cancer (CRC), even after patients undergo liver transplantation, according to a report published in Gastrointestinal Endoscopy. “Strict surveillance for colorectal cancer is warranted in this patient pop[...]
  • Sequential triple therapy produces high response rates in CLL

    on June 21st, 2017
    AT 14-ICML Lugano, Switzerland (FRONTLINE MEDICAL NEWS)– It’s in the BAG: For patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia, a regimen consisting of debulking with bendamustine (Treanda) followed sequentially by obinutuzumab (Gazyva) and venetoclax (Venclexta)[...]
  • GALEN safe and effective in relapsed and refractory follicular lymphoma

    on June 20th, 2017
    AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – For patients with relapsed or refractory follicular lymphoma, a pairing of lenalidomide (Revlimid) and obinutuzumab (Gazyva) appeared to be especially useful among patients who had disease progression within 24 months, based on results from[...]
  • Len plus anti-CD19 Mab MOR208 active against advanced DLBCL

    on June 20th, 2017
    AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – Combining lenalidomide (Revlimid) with an anti-CD19 monoclonal antibody labeled MOR208 showed promising activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were ineligible for stem cell transplant and [...]
  • Hitting BTK, PI3K pays off in B-cell malignancies

    on June 20th, 2017
    AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – A combination of ibrutinib and umbralisib, an investigational inhibitor of phosphatidylinostiol 3-kinase (PI3K), induced high response rates in patients with relapsed/refractory B-cell malignancies, with no dose-limiting toxicities, based o[...]
  • GOP senators shutting out physician input on reform – ASCO CEO

    on June 20th, 2017
    AT NCCN POLICY SUMMIT WASHINGTON (FRONTLINE MEDICAL NEWS) – Physician associations are having an easy time finding people on Capitol Hill willing to listen when it comes to health care reform, but it appears that the conversations are falling on deaf ears, according to Clifford Hudis, MD, CEO of t[...]
  • PROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCC

    on June 19th, 2017
    AT ASCO 2017 CHICAGO (FRONTLINE MEDICAL NEWS) – The antiangiogenic agent pazopanib is not efficacious when used as adjuvant therapy for resected renal cell carcinoma (RCC) with features that confer a high risk of recurrence, the PROTECT investigators reported at the annual meeting of the American [...]
Back to top